Companies › PeptiDream
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout May 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| PD-32766D (Copper-64 [64Cu] labeled peptide) 64Cu-labeled peptide targeting carbonic anhydrase IX (CA9) for PET/CT imaging | CA9 | Phase 1 | Clear Cell Renal Cell Carcinoma | May 2029 |
| PD-32766T (Actinium-225 [225Ac] labeled peptide) 225Ac-labeled peptide targeting carbonic anhydrase IX (CA9) for targeted alpha particle th | CA9 | Phase 1 | Clear Cell Renal Cell Carcinoma | May 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07688187 | PD-32766D (Copper-64 [64Cu] labeled peptide) | Phase 1 | Clear Cell Renal Cell Carcinoma | Oncology | May 2029 |
| NCT07688187 | PD-32766T (Actinium-225 [225Ac] labeled peptide) | Phase 1 | Clear Cell Renal Cell Carcinoma | Oncology | May 2029 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.